---
title: "Pfizer sees strong response for pediatric pneumonia vaccine in mid-stage trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302969708.md"
description: "Pfizer reported strong immune responses in a Phase 2 trial of its pediatric 25-valent pneumococcal conjugate vaccine (PF-07872412). The four-dose series demonstrated robust protection against all 25 serotypes and showed safety and tolerability comparable to Prevnar 20. The study involved approximately 400 full-term infants, with mild to moderate local reactions observed."
datetime: "2026-10-24T17:44:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302969708.md)
  - [en](https://longbridge.com/en/news/302969708.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302969708.md)
generator: "portal-rs"
---

# Pfizer sees strong response for pediatric pneumonia vaccine in mid-stage trial

Key points:

-   Data from a phase 2 trial of Pfizer's pediatric 25-valent pneumococcal conjugate vaccine PF-07872412 (25vPnC) showed that a four-dose series of the candidate provoked a robust immune response against all 25 serotypes.
-   The shot also demonstrated safety and tolerability similar to four doses of Prevnar 20 (pneumococcal 20-valent conjugate vaccine).
-   The study enrolled ~400 full-term infants with the primary objective comparing the safety of PF-07872412 to Prevnar 20. The four-dose series was given at 2, 4, 6, and 12 through 15 months of age.
-   Results showed that local injection site reactions were mild to moderate, with those reactions and systemic events similar between those given PF-07872412 and Prevnar 20.

**Disclaimer**

Content provided by Seeking Alpha is intended for information purposes only, and that Seeking Alpha does not offer any personalist investment advice and is not a licensed securities dealer, broker, US investment adviser or investment bank.

### Related Stocks

- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)

## Related News & Research

- [Pfizer reports Phase II data for 25vPnC infant vaccine candidate](https://longbridge.com/en/news/303115792.md)
- [Pfizer’s Elrexfio improves progression-free survival in Phase 3 multiple myeloma trial](https://longbridge.com/en/news/303214794.md)
- [Pfizer's Talzenna-Xtandi Gets Expanded FDA Approval For Earlier Prostate Cancer Treatment](https://longbridge.com/en/news/303172110.md)
- [Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting | PFE Stock News](https://longbridge.com/en/news/303118071.md)
- [Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026 | PFE Stock News](https://longbridge.com/en/news/302967727.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**